Biogen (BIIB) Tops Q2 EPS by $1.13, Offers FY Guidance

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.68, $1.13 better than the analyst estimate of $4.55. Revenue for the quarter came in at $2.78 billion versus the consensus estimate of $2.61 billion.

GUIDANCE:

Biogen sees FY2021 EPS of $17.50-$19.00, versus the consensus of $18.59. Biogen sees FY2021 revenue of $10.65-10.85 billion, versus the consensus of $10.63 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma